Pfizer and Biohaven recently completed a global commercialization deal worth up to $1.24 billion.
Compare PFE Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Pfizer
Paxlovid is practically guaranteed to be the biggest story.
These two stocks have been moving in opposite directions recently.
This may be another big year for coronavirus program revenue.
Pfizer gains access to Beam's gene-editing technology for three programs.
The deal boosts Pfizer's internal mRNA development effort.
Their performance in 2022 might be even better for them than 2021 was.
Income investors have a lot to like with these popular Robinhood stocks.
The two oral COVID-19 therapies use completely different mechanisms to fight the coronavirus.
Maybe, but some COVID-19 stocks could still move higher.